In Brief: Merck's Fosamax
Executive Summary
Merck's Fosamax: FDA's Endocrine & Metabolic Drugs Advisory Committee is scheduled to review Fosamax (alendronate, NDA 20-560) for osteoporosis July 13. The company disclosed June 5 that a three-year, 994-patient Phase III study to be presented at the Endocrine Society annual meeting June 14 found a 48% reduction in new vertebral fractures compared to placebo. The drug was licensed to Merck by Istituto Gentili of Pisa, Italy. The meeting will begin at 8 a.m. at the Holiday Inn in Silver Spring, Md...